Infant Bacterial Therapeutics AB (publ) (STO:IBT.B)
Sweden flag Sweden · Delayed Price · Currency is SEK
58.50
+1.30 (2.27%)
Feb 10, 2026, 11:32 AM CET

STO:IBT.B Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Other Revenue
-00.080.01-
-00.080.01-
Revenue Growth (YoY)
--94.80%541.67%--
Gross Profit
-00.080.01-
Selling, General & Admin
20.1520.3514.581.021.12
Research & Development
48.85125120.1264.843.56
Operating Expenses
69145.35134.6965.8244.67
Operating Income
-69-145.34-134.62-65.81-44.67
Interest Expense
----0.29-0.41
Interest & Investment Income
3.838.4411.550.65-
Other Non Operating Income (Expenses)
----0.09
Pretax Income
-65.17-136.91-123.07-65.45-44.99
Net Income
-65.17-136.91-123.07-65.45-44.99
Net Income to Common
-65.17-136.91-123.07-65.45-44.99
Shares Outstanding (Basic)
1313121111
Shares Outstanding (Diluted)
1313121111
Shares Change (YoY)
-8.95%10.14%--
EPS (Basic)
-4.84-10.16-9.95-5.83-4.01
EPS (Diluted)
-4.84-10.16-9.95-5.83-4.01
Free Cash Flow
-72.34-113.13-101.22-85.8-55.62
Free Cash Flow Per Share
-5.37-8.40-8.19-7.64-4.96
Gross Margin
-100.00%100.00%100.00%-
Operating Margin
--3633575.00%-174827.27%-548400.00%-
Profit Margin
--3422625.00%-159828.57%-545425.00%-
Free Cash Flow Margin
--2828325.00%-131453.25%-714958.33%-
EBIT
-69-145.34-134.62-65.81-44.67
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.